IRIS UniCatt

Danese, Silvio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.985
NA - Nord America 2.570
AS - Asia 2.072
SA - Sud America 410
AF - Africa 43
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.089
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.503
IT - Italia 1.471
DE - Germania 1.176
SG - Singapore 1.013
CN - Cina 563
SE - Svezia 390
BR - Brasile 337
UA - Ucraina 295
FR - Francia 145
GB - Regno Unito 125
IE - Irlanda 111
VN - Vietnam 105
ID - Indonesia 76
IN - India 72
FI - Finlandia 71
TR - Turchia 58
RU - Federazione Russa 57
CA - Canada 36
JP - Giappone 30
AR - Argentina 28
HK - Hong Kong 28
BD - Bangladesh 24
NL - Olanda 24
MX - Messico 21
PL - Polonia 19
IQ - Iraq 17
ZA - Sudafrica 16
KR - Corea 15
ES - Italia 14
RO - Romania 14
AT - Austria 12
IR - Iran 11
BE - Belgio 10
EC - Ecuador 9
PK - Pakistan 8
UZ - Uzbekistan 8
CH - Svizzera 7
PY - Paraguay 7
SA - Arabia Saudita 7
UY - Uruguay 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
AL - Albania 5
CZ - Repubblica Ceca 5
GR - Grecia 5
JO - Giordania 5
LT - Lituania 5
PT - Portogallo 5
AU - Australia 4
CL - Cile 4
DZ - Algeria 4
EU - Europa 4
HR - Croazia 4
KE - Kenya 4
MA - Marocco 4
AZ - Azerbaigian 3
BZ - Belize 3
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
ME - Montenegro 3
PH - Filippine 3
TN - Tunisia 3
CG - Congo 2
CI - Costa d'Avorio 2
EE - Estonia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
OM - Oman 2
PE - Perù 2
PS - Palestinian Territory 2
SN - Senegal 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BO - Bolivia 1
BY - Bielorussia 1
CM - Camerun 1
DK - Danimarca 1
GY - Guiana 1
HN - Honduras 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 9.088
Salva come PNG Salva come JPEG
Città #
Singapore 510
Chandler 418
Ashburn 230
Jacksonville 163
Milan 156
Rome 133
San Mateo 132
Dublin 109
Beijing 81
Nanjing 80
Nürnberg 78
Wilmington 72
Jakarta 67
Hefei 66
Ann Arbor 63
New York 61
Los Angeles 60
Boston 57
Dearborn 57
Munich 51
Princeton 46
Izmir 43
Ho Chi Minh City 34
Frankfurt am Main 32
Woodbridge 32
Houston 31
Nanchang 31
Redwood City 31
Moscow 30
Dallas 29
Turin 29
Hong Kong 28
Palermo 27
São Paulo 25
Hanoi 24
Seattle 24
Bari 23
Bremen 22
Cattolica 22
Detroit 22
Hebei 20
Marseille 20
Mountain View 20
Buffalo 19
Florence 19
Bologna 18
Lawrence 17
Shenyang 17
Tokyo 17
Boardman 15
Changsha 15
Fairfield 15
Kunming 15
University Park 15
Guangzhou 14
Naples 14
Genoa 13
Hangzhou 13
Kent 13
Pune 13
Jiaxing 12
Tianjin 12
Toronto 12
Zhengzhou 12
Chicago 11
Norwalk 11
Belo Horizonte 10
Brooklyn 10
Castignano 10
Manchester 10
Rio de Janeiro 10
Seoul 10
Treviso 10
Udine 10
Vienna 10
Andover 9
Augusta 9
Brussels 9
Catania 9
Denver 9
Warsaw 9
Brasília 8
Helsinki 8
Jinan 8
Leawood 8
Nuremberg 8
San Francisco 8
San Jose 8
Santa Clara 8
Shanghai 8
Simi Valley 8
Turku 8
Baghdad 7
Johannesburg 7
Lancaster 7
Montreal 7
Napoli 7
Parma 7
Roubaix 7
Taranto 7
Totale 3.909
Salva come PNG Salva come JPEG
Nome #
Ruolo dei fattori psicologici nelle malattie infiammatorie croniche intestinali 1.643
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 350
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. 231
-High prevalence of celiac disease in patients with lactose intolerance 212
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 190
Early atherosclerosis in patients with inflammatory bowel disease. 182
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 179
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 179
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 176
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 159
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD) 156
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 154
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 154
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 139
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease 132
-Extraintestinal manifestations in inflammatory Bowel disease. 130
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 130
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication 128
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? 126
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 124
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 121
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. 120
A novel pathogenic role for microvasculature in inflammatory bowel disease. 118
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation 117
Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients 113
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events 108
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing 107
Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine 107
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. 106
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 105
Biological therapies for inflammatory bowel disease: research drives clinics. 104
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer 104
Gender, chronic infection and myocardial infarction 102
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 95
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 95
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 93
Severe liver injury associated with zafirlukast 92
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement 92
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 90
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 90
Elevated homocysteine levels in patients with Raynaud's syndrome 88
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease 88
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. 87
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 87
Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases 84
Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment. 82
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery 82
Balanced propofol sedation administered by nonanesthesiologists: The first Italian experience 81
ag) CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems. 80
ag) Antibody to alpha4beta7 integrin for ulcerative colitis. 78
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease 77
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial 75
A) CD40L-positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation. 71
Folate in gastrointestinal health and disease 70
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease 70
Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate 70
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. 68
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study 64
Thrombotic complications in inflammatory bowel disease: a multifactorial etiology 64
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 62
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease 61
Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study 59
Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease 58
ag) Chemokines in inflammatory bowel disease. 57
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis 55
Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study 55
Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality 54
Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials 54
-Antibody to alpha4beta7 integrin for ulcerative colitis 54
High prevalence of Helicobacter priori type I virulent strains in patients with systemic sclerosis [6] (multiple letters) 48
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease 47
Assessment of prothrombotic risk in patients with Behçet's disease should include homocysteine plasma levels 46
Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer 43
Totale 9.172
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.896
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021431 0 0 0 0 0 35 85 23 105 37 118 28
2021/2022689 48 66 19 49 32 18 17 127 27 38 113 135
2022/20231.309 146 164 101 202 95 156 66 117 154 26 42 40
2023/2024771 41 190 48 46 62 78 50 32 22 47 69 86
2024/20251.274 46 38 129 52 125 50 70 75 158 121 238 172
2025/20261.897 507 115 218 411 617 29 0 0 0 0 0 0
Totale 9.172